Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Burns | 31 | 2019 | 110 | 6.190 |
Why?
|
Burn Units | 17 | 2016 | 28 | 3.340 |
Why?
|
Image Enhancement | 18 | 2017 | 70 | 2.000 |
Why?
|
Image Interpretation, Computer-Assisted | 13 | 2018 | 112 | 1.940 |
Why?
|
Disaster Planning | 11 | 2016 | 29 | 1.920 |
Why?
|
Magnetic Resonance Imaging | 16 | 2018 | 1210 | 1.860 |
Why?
|
Imaging, Three-Dimensional | 11 | 2015 | 138 | 1.510 |
Why?
|
Mass Casualty Incidents | 9 | 2016 | 18 | 1.370 |
Why?
|
Helium | 8 | 2011 | 9 | 1.200 |
Why?
|
Artifacts | 10 | 2017 | 39 | 1.120 |
Why?
|
Image Processing, Computer-Assisted | 10 | 2019 | 247 | 1.100 |
Why?
|
Algorithms | 17 | 2019 | 460 | 1.010 |
Why?
|
Humans | 95 | 2019 | 28999 | 0.990 |
Why?
|
Referral and Consultation | 4 | 2014 | 111 | 0.970 |
Why?
|
Magnetic Resonance Angiography | 8 | 2016 | 66 | 0.970 |
Why?
|
Emergency Medical Services | 9 | 2015 | 153 | 0.920 |
Why?
|
Contrast Media | 12 | 2017 | 127 | 0.850 |
Why?
|
Liver | 9 | 2019 | 466 | 0.840 |
Why?
|
Length of Stay | 9 | 2019 | 296 | 0.810 |
Why?
|
Adult | 37 | 2019 | 8644 | 0.730 |
Why?
|
Immunoglobulin E | 1 | 2019 | 47 | 0.730 |
Why?
|
Autoimmunity | 1 | 2019 | 26 | 0.730 |
Why?
|
Autoantibodies | 1 | 2019 | 41 | 0.720 |
Why?
|
Regional Health Planning | 3 | 2014 | 6 | 0.680 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2019 | 54 | 0.680 |
Why?
|
Hospital Mortality | 4 | 2018 | 190 | 0.680 |
Why?
|
Male | 47 | 2019 | 18231 | 0.660 |
Why?
|
Phantoms, Imaging | 8 | 2018 | 56 | 0.660 |
Why?
|
Burns, Inhalation | 1 | 2017 | 1 | 0.650 |
Why?
|
Lung | 6 | 2013 | 231 | 0.650 |
Why?
|
Female | 46 | 2019 | 18453 | 0.650 |
Why?
|
Dermatitis, Atopic | 1 | 2019 | 85 | 0.650 |
Why?
|
Middle Aged | 34 | 2019 | 11242 | 0.640 |
Why?
|
Wounds, Nonpenetrating | 5 | 2014 | 91 | 0.610 |
Why?
|
Echo-Planar Imaging | 3 | 2018 | 16 | 0.610 |
Why?
|
Spleen | 4 | 2014 | 80 | 0.610 |
Why?
|
Biomedical Research | 1 | 2017 | 164 | 0.560 |
Why?
|
Emergency Treatment | 2 | 2013 | 43 | 0.560 |
Why?
|
Curriculum | 2 | 2016 | 191 | 0.540 |
Why?
|
Blood Transfusion | 4 | 2019 | 72 | 0.530 |
Why?
|
Reproducibility of Results | 15 | 2018 | 713 | 0.530 |
Why?
|
Young Adult | 13 | 2019 | 2409 | 0.530 |
Why?
|
Adolescent | 13 | 2019 | 3232 | 0.520 |
Why?
|
Cardiopulmonary Bypass | 4 | 2002 | 59 | 0.510 |
Why?
|
Hospitalization | 4 | 2012 | 403 | 0.500 |
Why?
|
Injury Severity Score | 9 | 2017 | 117 | 0.490 |
Why?
|
Smoke Inhalation Injury | 3 | 2016 | 6 | 0.490 |
Why?
|
Cooperative Behavior | 1 | 2014 | 77 | 0.490 |
Why?
|
Retrospective Studies | 17 | 2016 | 3073 | 0.480 |
Why?
|
Pulmonary Gas Exchange | 2 | 2009 | 14 | 0.470 |
Why?
|
Treatment Outcome | 15 | 2018 | 3149 | 0.470 |
Why?
|
Sensitivity and Specificity | 12 | 2016 | 524 | 0.460 |
Why?
|
Surge Capacity | 5 | 2014 | 9 | 0.450 |
Why?
|
Carbon Dioxide | 1 | 2012 | 36 | 0.440 |
Why?
|
Child | 8 | 2019 | 2130 | 0.430 |
Why?
|
Regional Medical Programs | 1 | 2011 | 5 | 0.430 |
Why?
|
Emergency Service, Hospital | 2 | 2012 | 428 | 0.420 |
Why?
|
Stevens-Johnson Syndrome | 3 | 2018 | 6 | 0.420 |
Why?
|
Aged | 19 | 2019 | 9677 | 0.420 |
Why?
|
Respiratory Insufficiency | 1 | 2012 | 60 | 0.420 |
Why?
|
Intubation, Intratracheal | 1 | 2012 | 68 | 0.410 |
Why?
|
Gadolinium DTPA | 3 | 2015 | 13 | 0.410 |
Why?
|
Child, Preschool | 6 | 2019 | 1156 | 0.410 |
Why?
|
Severity of Illness Index | 6 | 2019 | 890 | 0.400 |
Why?
|
North Carolina | 8 | 2015 | 1643 | 0.380 |
Why?
|
Wound Healing | 7 | 2019 | 180 | 0.380 |
Why?
|
Mafenide | 1 | 2009 | 1 | 0.380 |
Why?
|
Plasma Exchange | 1 | 2009 | 10 | 0.380 |
Why?
|
Amphotericin B | 1 | 2009 | 11 | 0.380 |
Why?
|
Shock | 1 | 2009 | 23 | 0.370 |
Why?
|
Guideline Adherence | 1 | 2010 | 110 | 0.370 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 43 | 0.360 |
Why?
|
Asthma | 2 | 2009 | 385 | 0.360 |
Why?
|
Lung Diseases | 3 | 2007 | 45 | 0.350 |
Why?
|
Surgical Wound Infection | 1 | 2009 | 74 | 0.350 |
Why?
|
United States | 14 | 2019 | 3700 | 0.350 |
Why?
|
Pulmonary Ventilation | 1 | 2008 | 11 | 0.350 |
Why?
|
Prospective Studies | 11 | 2019 | 1989 | 0.340 |
Why?
|
Societies, Medical | 4 | 2014 | 152 | 0.330 |
Why?
|
Postoperative Complications | 3 | 2007 | 676 | 0.330 |
Why?
|
Motion | 3 | 2018 | 12 | 0.330 |
Why?
|
Program Evaluation | 4 | 2016 | 169 | 0.320 |
Why?
|
Aged, 80 and over | 9 | 2019 | 3728 | 0.320 |
Why?
|
Liver Neoplasms | 4 | 2019 | 171 | 0.320 |
Why?
|
Brain | 3 | 2018 | 956 | 0.320 |
Why?
|
Time Factors | 13 | 2018 | 2030 | 0.320 |
Why?
|
Skin | 2 | 2019 | 205 | 0.310 |
Why?
|
Intensive Care Units | 2 | 2018 | 126 | 0.310 |
Why?
|
Skin, Artificial | 5 | 2019 | 33 | 0.310 |
Why?
|
Survival Rate | 5 | 2018 | 816 | 0.300 |
Why?
|
Health Services Accessibility | 1 | 2008 | 232 | 0.300 |
Why?
|
Coronary Artery Bypass | 3 | 2006 | 105 | 0.300 |
Why?
|
Carrier Proteins | 2 | 2009 | 114 | 0.290 |
Why?
|
Respiratory Hypersensitivity | 1 | 2005 | 2 | 0.290 |
Why?
|
Pancreas | 1 | 2005 | 76 | 0.280 |
Why?
|
Organizational Objectives | 3 | 2014 | 26 | 0.280 |
Why?
|
Prognosis | 3 | 2019 | 1384 | 0.270 |
Why?
|
Respiration, Artificial | 4 | 2018 | 98 | 0.270 |
Why?
|
Kidney | 2 | 2006 | 495 | 0.270 |
Why?
|
Organometallic Compounds | 2 | 2015 | 18 | 0.270 |
Why?
|
Southeastern United States | 3 | 2014 | 78 | 0.270 |
Why?
|
Enteral Nutrition | 2 | 2006 | 30 | 0.270 |
Why?
|
Splenic Artery | 2 | 2014 | 12 | 0.270 |
Why?
|
Pain | 3 | 2015 | 273 | 0.260 |
Why?
|
Radiography, Interventional | 2 | 2014 | 34 | 0.260 |
Why?
|
Positron-Emission Tomography | 1 | 2005 | 169 | 0.260 |
Why?
|
Catechol O-Methyltransferase | 2 | 2015 | 14 | 0.260 |
Why?
|
Embolization, Therapeutic | 2 | 2014 | 82 | 0.250 |
Why?
|
Biocompatible Materials | 3 | 2019 | 219 | 0.250 |
Why?
|
Hernia | 2 | 2004 | 12 | 0.240 |
Why?
|
Aortic Rupture | 1 | 2002 | 7 | 0.230 |
Why?
|
Skin Transplantation | 3 | 2019 | 52 | 0.230 |
Why?
|
Infant | 4 | 2014 | 936 | 0.230 |
Why?
|
Bicycling | 1 | 2002 | 12 | 0.220 |
Why?
|
Aorta, Thoracic | 1 | 2002 | 75 | 0.220 |
Why?
|
Thoracic Injuries | 1 | 2002 | 50 | 0.210 |
Why?
|
Feasibility Studies | 6 | 2015 | 255 | 0.210 |
Why?
|
Debridement | 2 | 2019 | 41 | 0.210 |
Why?
|
Tumor Suppressor Proteins | 1 | 2001 | 70 | 0.210 |
Why?
|
Respiration | 2 | 2013 | 26 | 0.210 |
Why?
|
Isotopes | 6 | 2011 | 11 | 0.210 |
Why?
|
Ischemia | 1 | 2001 | 90 | 0.210 |
Why?
|
Neoplasm Proteins | 1 | 2001 | 136 | 0.200 |
Why?
|
Jejunostomy | 1 | 1999 | 6 | 0.200 |
Why?
|
Equipment Design | 5 | 2019 | 175 | 0.190 |
Why?
|
Aprotinin | 1 | 1999 | 7 | 0.190 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2010 | 15 | 0.190 |
Why?
|
Serine Proteinase Inhibitors | 1 | 1999 | 7 | 0.190 |
Why?
|
Multiple Trauma | 1 | 1999 | 38 | 0.190 |
Why?
|
Postoperative Hemorrhage | 1 | 1999 | 38 | 0.190 |
Why?
|
Antibodies, Antinuclear | 1 | 2019 | 18 | 0.180 |
Why?
|
Practice Guidelines as Topic | 5 | 2017 | 381 | 0.180 |
Why?
|
Inflammation | 1 | 2002 | 498 | 0.180 |
Why?
|
Blood Preservation | 1 | 2018 | 10 | 0.180 |
Why?
|
Guidelines as Topic | 1 | 2019 | 45 | 0.180 |
Why?
|
Cohort Studies | 3 | 2012 | 1694 | 0.180 |
Why?
|
Adipose Tissue | 3 | 2018 | 336 | 0.180 |
Why?
|
Fatty Liver | 2 | 2018 | 70 | 0.170 |
Why?
|
Expert Testimony | 1 | 2018 | 11 | 0.170 |
Why?
|
Coronary Disease | 1 | 1999 | 215 | 0.170 |
Why?
|
Wounds and Injuries | 3 | 2012 | 251 | 0.170 |
Why?
|
Fluid Therapy | 2 | 2009 | 27 | 0.170 |
Why?
|
Critical Illness | 1 | 2018 | 85 | 0.170 |
Why?
|
Prostate | 1 | 2018 | 68 | 0.170 |
Why?
|
Nurse Practitioners | 1 | 2017 | 7 | 0.160 |
Why?
|
Salaries and Fringe Benefits | 1 | 2017 | 11 | 0.160 |
Why?
|
Physician Assistants | 1 | 2017 | 24 | 0.160 |
Why?
|
Bronchoscopy | 1 | 2017 | 56 | 0.160 |
Why?
|
Abdominal Injuries | 2 | 2007 | 34 | 0.160 |
Why?
|
Patient Transfer | 2 | 2014 | 31 | 0.150 |
Why?
|
Congresses as Topic | 2 | 2018 | 41 | 0.150 |
Why?
|
Age Factors | 5 | 2012 | 1129 | 0.150 |
Why?
|
Blast Injuries | 2 | 2014 | 24 | 0.150 |
Why?
|
Tissue Engineering | 2 | 2019 | 611 | 0.150 |
Why?
|
Acute Lung Injury | 1 | 2016 | 31 | 0.150 |
Why?
|
Clinical Competence | 2 | 2016 | 303 | 0.150 |
Why?
|
Arm Injuries | 1 | 2016 | 14 | 0.150 |
Why?
|
Thrombosis | 1 | 2016 | 56 | 0.150 |
Why?
|
Surgery, Plastic | 1 | 2016 | 26 | 0.150 |
Why?
|
Calibration | 2 | 2013 | 24 | 0.150 |
Why?
|
Awareness | 1 | 2016 | 27 | 0.140 |
Why?
|
Temperature | 1 | 2015 | 51 | 0.140 |
Why?
|
Gadolinium | 1 | 2015 | 18 | 0.140 |
Why?
|
Propranolol | 1 | 2015 | 15 | 0.140 |
Why?
|
Computer Simulation | 3 | 2018 | 206 | 0.140 |
Why?
|
Burns, Electric | 1 | 2014 | 2 | 0.140 |
Why?
|
Bone and Bones | 1 | 2015 | 84 | 0.140 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2015 | 64 | 0.130 |
Why?
|
Administration, Cutaneous | 2 | 2019 | 110 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2014 | 26 | 0.130 |
Why?
|
Burns, Chemical | 1 | 2014 | 7 | 0.130 |
Why?
|
Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 2 | 0.130 |
Why?
|
Meglumine | 1 | 2014 | 3 | 0.130 |
Why?
|
Security Measures | 1 | 2014 | 2 | 0.130 |
Why?
|
Pain Measurement | 2 | 2015 | 375 | 0.130 |
Why?
|
Bioterrorism | 1 | 2014 | 4 | 0.130 |
Why?
|
Earthquakes | 1 | 2014 | 1 | 0.130 |
Why?
|
Health Personnel | 1 | 2015 | 107 | 0.130 |
Why?
|
Civil Defense | 1 | 2014 | 6 | 0.130 |
Why?
|
Mobile Health Units | 1 | 2014 | 4 | 0.130 |
Why?
|
Hospitals, Military | 1 | 2014 | 7 | 0.130 |
Why?
|
Orthopedic Procedures | 1 | 2015 | 92 | 0.130 |
Why?
|
Information Storage and Retrieval | 1 | 2014 | 26 | 0.130 |
Why?
|
User-Computer Interface | 1 | 2014 | 34 | 0.130 |
Why?
|
Transportation of Patients | 1 | 2014 | 15 | 0.130 |
Why?
|
Health Resources | 1 | 2014 | 31 | 0.130 |
Why?
|
Vascular Diseases | 1 | 2014 | 62 | 0.130 |
Why?
|
Quality Assurance, Health Care | 1 | 2014 | 62 | 0.130 |
Why?
|
Drug Combinations | 2 | 2015 | 83 | 0.130 |
Why?
|
Bile Ducts | 1 | 2013 | 19 | 0.130 |
Why?
|
Blood Vessels | 1 | 2014 | 51 | 0.120 |
Why?
|
Hospitals | 1 | 2014 | 75 | 0.120 |
Why?
|
Program Development | 1 | 2014 | 88 | 0.120 |
Why?
|
Christian Science | 1 | 1993 | 1 | 0.120 |
Why?
|
Pressure Ulcer | 1 | 1993 | 6 | 0.120 |
Why?
|
Pulmonary Circulation | 1 | 2013 | 4 | 0.120 |
Why?
|
Homes for the Aged | 1 | 1993 | 11 | 0.120 |
Why?
|
Hospital Bed Capacity | 2 | 2013 | 6 | 0.120 |
Why?
|
Sarcoidosis | 1 | 2013 | 29 | 0.120 |
Why?
|
Models, Biological | 1 | 2015 | 372 | 0.120 |
Why?
|
Pediatrics | 1 | 2014 | 133 | 0.120 |
Why?
|
Patient Care Team | 1 | 2014 | 122 | 0.120 |
Why?
|
Triage | 4 | 2014 | 69 | 0.120 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2015 | 83 | 0.120 |
Why?
|
Evidence-Based Medicine | 1 | 2014 | 209 | 0.120 |
Why?
|
Infant, Newborn | 1 | 2014 | 575 | 0.110 |
Why?
|
Prevalence | 2 | 2012 | 912 | 0.110 |
Why?
|
Spin Labels | 1 | 2012 | 26 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 341 | 0.110 |
Why?
|
Robotics | 1 | 2014 | 126 | 0.110 |
Why?
|
Tidal Volume | 1 | 2012 | 13 | 0.110 |
Why?
|
Quality Control | 1 | 2012 | 41 | 0.110 |
Why?
|
California | 1 | 2012 | 61 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 4 | 2014 | 879 | 0.110 |
Why?
|
Emergencies | 1 | 2012 | 48 | 0.110 |
Why?
|
Confidence Intervals | 1 | 2012 | 141 | 0.110 |
Why?
|
Patient Admission | 1 | 2012 | 54 | 0.110 |
Why?
|
General Surgery | 1 | 2012 | 82 | 0.110 |
Why?
|
Animals | 7 | 2019 | 7360 | 0.100 |
Why?
|
Arteries | 1 | 2011 | 61 | 0.100 |
Why?
|
Treatment Failure | 2 | 2014 | 163 | 0.100 |
Why?
|
Intestines | 2 | 2001 | 52 | 0.100 |
Why?
|
Breast Neoplasms | 1 | 2017 | 700 | 0.100 |
Why?
|
Laparotomy | 2 | 2007 | 32 | 0.100 |
Why?
|
Stress, Psychological | 1 | 2012 | 215 | 0.100 |
Why?
|
Risk Factors | 5 | 2016 | 3569 | 0.100 |
Why?
|
Skin Absorption | 1 | 2009 | 12 | 0.090 |
Why?
|
Anti-Infective Agents, Local | 1 | 2009 | 12 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 1253 | 0.090 |
Why?
|
Regenerative Medicine | 1 | 2012 | 185 | 0.090 |
Why?
|
Arabidopsis Proteins | 1 | 2009 | 2 | 0.090 |
Why?
|
Arabidopsis | 1 | 2009 | 3 | 0.090 |
Why?
|
Risk Assessment | 2 | 2012 | 1319 | 0.090 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2009 | 17 | 0.090 |
Why?
|
Lactic Acid | 1 | 2009 | 55 | 0.090 |
Why?
|
Radioisotopes | 2 | 2006 | 5 | 0.090 |
Why?
|
Protein Subunits | 1 | 2009 | 36 | 0.090 |
Why?
|
Radiopharmaceuticals | 2 | 2010 | 85 | 0.090 |
Why?
|
Salvage Therapy | 1 | 2009 | 118 | 0.090 |
Why?
|
Postoperative Care | 1 | 2009 | 75 | 0.090 |
Why?
|
Urine | 1 | 2009 | 59 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 257 | 0.090 |
Why?
|
Patient Selection | 1 | 2010 | 264 | 0.080 |
Why?
|
Reconstructive Surgical Procedures | 2 | 2013 | 213 | 0.080 |
Why?
|
Air | 1 | 2007 | 6 | 0.080 |
Why?
|
Fourier Analysis | 1 | 2007 | 7 | 0.080 |
Why?
|
Graft Survival | 1 | 2009 | 233 | 0.080 |
Why?
|
Necrosis | 2 | 2015 | 53 | 0.080 |
Why?
|
Collagen | 3 | 2019 | 227 | 0.080 |
Why?
|
Cerebrovascular Circulation | 2 | 2006 | 90 | 0.080 |
Why?
|
Noble Gases | 1 | 2007 | 1 | 0.080 |
Why?
|
Xenon Isotopes | 1 | 2007 | 1 | 0.080 |
Why?
|
Anastomosis, Surgical | 1 | 2007 | 50 | 0.080 |
Why?
|
Knee Joint | 1 | 2008 | 115 | 0.080 |
Why?
|
Protons | 2 | 2018 | 22 | 0.080 |
Why?
|
Colon | 1 | 2007 | 57 | 0.080 |
Why?
|
Pulmonary Emphysema | 1 | 2006 | 8 | 0.080 |
Why?
|
Vena Cava Filters | 1 | 2006 | 14 | 0.080 |
Why?
|
Sepsis | 1 | 2007 | 138 | 0.070 |
Why?
|
Trauma Severity Indices | 2 | 2018 | 54 | 0.070 |
Why?
|
Pulmonary Embolism | 1 | 2006 | 44 | 0.070 |
Why?
|
Allergens | 1 | 2005 | 17 | 0.070 |
Why?
|
Rats, Inbred BN | 1 | 2005 | 33 | 0.070 |
Why?
|
Clinical Protocols | 2 | 2017 | 89 | 0.070 |
Why?
|
Facial Injuries | 1 | 2005 | 14 | 0.070 |
Why?
|
Predictive Value of Tests | 2 | 2012 | 781 | 0.070 |
Why?
|
Cause of Death | 2 | 2011 | 222 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2005 | 55 | 0.070 |
Why?
|
Swine | 2 | 2019 | 201 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2004 | 25 | 0.070 |
Why?
|
Urea | 1 | 2004 | 33 | 0.070 |
Why?
|
Abbreviated Injury Scale | 2 | 2006 | 57 | 0.070 |
Why?
|
Blood Pressure | 1 | 2009 | 858 | 0.070 |
Why?
|
Foot Diseases | 1 | 2004 | 5 | 0.070 |
Why?
|
Indoles | 1 | 2004 | 61 | 0.070 |
Why?
|
Glucose | 1 | 2005 | 169 | 0.060 |
Why?
|
Multiple Organ Failure | 2 | 2017 | 8 | 0.060 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 157 | 0.060 |
Why?
|
Bupivacaine | 1 | 2004 | 56 | 0.060 |
Why?
|
Betamethasone | 1 | 2004 | 52 | 0.060 |
Why?
|
Pilot Projects | 2 | 2016 | 465 | 0.060 |
Why?
|
Blood Flow Velocity | 2 | 2014 | 61 | 0.060 |
Why?
|
Incidence | 2 | 2017 | 1097 | 0.060 |
Why?
|
Early Diagnosis | 2 | 2018 | 59 | 0.060 |
Why?
|
Anesthetics, Local | 1 | 2004 | 93 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2015 | 2147 | 0.060 |
Why?
|
Disease Progression | 2 | 2018 | 596 | 0.060 |
Why?
|
Complement C3a | 1 | 2002 | 2 | 0.060 |
Why?
|
Pancreatic Elastase | 1 | 2002 | 2 | 0.060 |
Why?
|
Intraoperative Period | 2 | 1999 | 37 | 0.060 |
Why?
|
Rats | 2 | 2005 | 1699 | 0.060 |
Why?
|
Interleukin-8 | 1 | 2002 | 23 | 0.060 |
Why?
|
Sample Size | 2 | 2014 | 38 | 0.060 |
Why?
|
Glucocorticoids | 1 | 2004 | 152 | 0.060 |
Why?
|
Smoking | 1 | 2006 | 438 | 0.060 |
Why?
|
Tissue Scaffolds | 2 | 2019 | 386 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 155 | 0.060 |
Why?
|
Stroke | 1 | 2008 | 556 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2006 | 384 | 0.060 |
Why?
|
Data Interpretation, Statistical | 2 | 2014 | 106 | 0.060 |
Why?
|
Inflammation Mediators | 1 | 2002 | 103 | 0.060 |
Why?
|
Medicaid | 2 | 2014 | 79 | 0.060 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2001 | 6 | 0.060 |
Why?
|
Body Water | 2 | 2014 | 8 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2002 | 227 | 0.060 |
Why?
|
Heart Diseases | 1 | 2002 | 101 | 0.050 |
Why?
|
Resuscitation | 2 | 2013 | 58 | 0.050 |
Why?
|
Cystadenoma | 1 | 2001 | 2 | 0.050 |
Why?
|
Cystadenocarcinoma | 1 | 2001 | 3 | 0.050 |
Why?
|
Genotype | 2 | 2015 | 827 | 0.050 |
Why?
|
Milk Proteins | 1 | 2001 | 2 | 0.050 |
Why?
|
Sp1 Transcription Factor | 1 | 2001 | 4 | 0.050 |
Why?
|
Cyclins | 1 | 2001 | 5 | 0.050 |
Why?
|
Cysts | 1 | 2001 | 18 | 0.050 |
Why?
|
Intestinal Mucosa | 1 | 2001 | 63 | 0.050 |
Why?
|
Interleukin-2 | 1 | 2001 | 33 | 0.050 |
Why?
|
Radiography | 1 | 2002 | 348 | 0.050 |
Why?
|
Trans-Activators | 1 | 2001 | 43 | 0.050 |
Why?
|
Liver Diseases | 1 | 2001 | 62 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 448 | 0.050 |
Why?
|
Medicare | 2 | 2013 | 178 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2001 | 137 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2001 | 131 | 0.050 |
Why?
|
Infarction | 1 | 1999 | 4 | 0.050 |
Why?
|
Discriminant Analysis | 1 | 1999 | 18 | 0.050 |
Why?
|
Mice | 3 | 2019 | 2331 | 0.050 |
Why?
|
Intestinal Obstruction | 1 | 1999 | 10 | 0.050 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 22 | 0.050 |
Why?
|
Intestinal Perforation | 1 | 1999 | 9 | 0.050 |
Why?
|
Hematocrit | 1 | 1999 | 23 | 0.050 |
Why?
|
Platelet Transfusion | 1 | 1999 | 16 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2002 | 252 | 0.050 |
Why?
|
Infusions, Intravenous | 1 | 1999 | 88 | 0.050 |
Why?
|
Erythrocyte Transfusion | 1 | 1999 | 33 | 0.050 |
Why?
|
Chondroitin Sulfates | 2 | 2012 | 23 | 0.050 |
Why?
|
Body Surface Area | 1 | 2019 | 16 | 0.050 |
Why?
|
Transplantation, Autologous | 1 | 2019 | 83 | 0.050 |
Why?
|
Movement | 1 | 2019 | 34 | 0.050 |
Why?
|
Keratinocytes | 1 | 2019 | 26 | 0.050 |
Why?
|
Acetone | 1 | 2018 | 1 | 0.050 |
Why?
|
Acute Disease | 1 | 1999 | 248 | 0.050 |
Why?
|
Linear Models | 2 | 2012 | 433 | 0.040 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 22 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2019 | 151 | 0.040 |
Why?
|
Administration, Inhalation | 2 | 2010 | 92 | 0.040 |
Why?
|
Health Policy | 1 | 2019 | 73 | 0.040 |
Why?
|
Professional Practice | 1 | 2018 | 25 | 0.040 |
Why?
|
Fibroblasts | 1 | 2019 | 106 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2018 | 38 | 0.040 |
Why?
|
Neuropsychological Tests | 1 | 1999 | 388 | 0.040 |
Why?
|
Mice, Nude | 1 | 2019 | 277 | 0.040 |
Why?
|
Hydrogels | 1 | 2019 | 101 | 0.040 |
Why?
|
Interdisciplinary Communication | 1 | 2018 | 53 | 0.040 |
Why?
|
Bacteremia | 1 | 2017 | 50 | 0.040 |
Why?
|
Registries | 2 | 2010 | 288 | 0.040 |
Why?
|
Regeneration | 1 | 2019 | 165 | 0.040 |
Why?
|
Breast | 1 | 2017 | 48 | 0.040 |
Why?
|
Safety | 2 | 2007 | 86 | 0.040 |
Why?
|
Wisconsin | 1 | 2016 | 17 | 0.040 |
Why?
|
False Positive Reactions | 1 | 2016 | 23 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2018 | 121 | 0.040 |
Why?
|
Research Design | 1 | 2018 | 281 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2019 | 585 | 0.040 |
Why?
|
Observer Variation | 1 | 2016 | 96 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 308 | 0.040 |
Why?
|
Education, Nursing, Continuing | 1 | 2015 | 2 | 0.040 |
Why?
|
Biliary Tract | 1 | 2015 | 7 | 0.040 |
Why?
|
Hepatic Artery | 1 | 2015 | 10 | 0.040 |
Why?
|
Portal Vein | 1 | 2015 | 17 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2015 | 86 | 0.040 |
Why?
|
Educational Measurement | 1 | 2016 | 108 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2016 | 143 | 0.030 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 49 | 0.030 |
Why?
|
Drug Synergism | 1 | 2015 | 65 | 0.030 |
Why?
|
Pregnancy | 1 | 2018 | 744 | 0.030 |
Why?
|
Finite Element Analysis | 1 | 2015 | 80 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2014 | 19 | 0.030 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 37 | 0.030 |
Why?
|
Organizational Case Studies | 1 | 2014 | 11 | 0.030 |
Why?
|
Haiti | 1 | 2014 | 1 | 0.030 |
Why?
|
Leg | 1 | 2014 | 52 | 0.030 |
Why?
|
History, 19th Century | 1 | 2014 | 18 | 0.030 |
Why?
|
Equipment Failure Analysis | 1 | 2014 | 43 | 0.030 |
Why?
|
Organizational Innovation | 1 | 2014 | 30 | 0.030 |
Why?
|
International Cooperation | 1 | 2014 | 25 | 0.030 |
Why?
|
History, 21st Century | 1 | 2014 | 50 | 0.030 |
Why?
|
History, 20th Century | 1 | 2014 | 72 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 161 | 0.030 |
Why?
|
Angiography | 1 | 2014 | 79 | 0.030 |
Why?
|
Trauma Centers | 1 | 2014 | 85 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2015 | 521 | 0.030 |
Why?
|
Texas | 1 | 1993 | 41 | 0.030 |
Why?
|
Forecasting | 1 | 2014 | 134 | 0.030 |
Why?
|
Reference Values | 1 | 2013 | 233 | 0.030 |
Why?
|
Southwestern United States | 1 | 2013 | 2 | 0.030 |
Why?
|
Bandages | 1 | 2013 | 34 | 0.030 |
Why?
|
Nursing Homes | 1 | 1993 | 30 | 0.030 |
Why?
|
Patient Compliance | 1 | 2015 | 207 | 0.030 |
Why?
|
Brain Mapping | 1 | 2013 | 182 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2012 | 52 | 0.030 |
Why?
|
Larynx | 1 | 2012 | 18 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2012 | 28 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 36 | 0.030 |
Why?
|
Pain Threshold | 1 | 2012 | 94 | 0.030 |
Why?
|
Cell Transplantation | 1 | 2012 | 64 | 0.030 |
Why?
|
Blood Vessel Prosthesis | 1 | 2012 | 79 | 0.030 |
Why?
|
Liver Transplantation | 1 | 2012 | 113 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 137 | 0.030 |
Why?
|
Analgesics | 1 | 2012 | 125 | 0.030 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 220 | 0.030 |
Why?
|
Models, Anatomic | 1 | 2011 | 36 | 0.030 |
Why?
|
Workers' Compensation | 1 | 2010 | 4 | 0.030 |
Why?
|
Regression Analysis | 1 | 2011 | 289 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2015 | 493 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 308 | 0.030 |
Why?
|
Pollen | 1 | 2009 | 2 | 0.020 |
Why?
|
Seeds | 1 | 2009 | 9 | 0.020 |
Why?
|
Embryonic Development | 1 | 2009 | 9 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2009 | 59 | 0.020 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 75 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2010 | 166 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 255 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 326 | 0.020 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2007 | 11 | 0.020 |
Why?
|
Glasgow Coma Scale | 1 | 2007 | 28 | 0.020 |
Why?
|
Colostomy | 1 | 2007 | 4 | 0.020 |
Why?
|
Colon, Sigmoid | 1 | 2007 | 4 | 0.020 |
Why?
|
Abdominal Abscess | 1 | 2007 | 7 | 0.020 |
Why?
|
Colectomy | 1 | 2007 | 25 | 0.020 |
Why?
|
Wounds, Penetrating | 1 | 2007 | 13 | 0.020 |
Why?
|
Ileum | 1 | 2007 | 13 | 0.020 |
Why?
|
Pneumonia | 1 | 2007 | 60 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2007 | 112 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 2007 | 61 | 0.020 |
Why?
|
Phenotype | 1 | 2009 | 664 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2012 | 583 | 0.020 |
Why?
|
Hemodynamics | 1 | 2007 | 152 | 0.020 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2006 | 2 | 0.020 |
Why?
|
Carbon Monoxide | 1 | 2006 | 6 | 0.020 |
Why?
|
Spirometry | 1 | 2006 | 33 | 0.020 |
Why?
|
Vital Capacity | 1 | 2006 | 44 | 0.020 |
Why?
|
Reoperation | 1 | 2007 | 195 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 576 | 0.020 |
Why?
|
Forced Expiratory Volume | 1 | 2006 | 112 | 0.020 |
Why?
|
Steroids | 1 | 2006 | 36 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2006 | 53 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 98 | 0.020 |
Why?
|
Eyelids | 1 | 2005 | 10 | 0.020 |
Why?
|
Esthetics | 1 | 2005 | 12 | 0.020 |
Why?
|
Skin Pigmentation | 1 | 2005 | 24 | 0.020 |
Why?
|
Decision Making | 1 | 2007 | 189 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2004 | 45 | 0.020 |
Why?
|
Heel | 1 | 2004 | 6 | 0.020 |
Why?
|
Injections, Intralesional | 1 | 2004 | 13 | 0.020 |
Why?
|
Ehlers-Danlos Syndrome | 1 | 2004 | 4 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2006 | 283 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2004 | 285 | 0.020 |
Why?
|
5' Untranslated Regions | 1 | 2001 | 4 | 0.010 |
Why?
|
STAT5 Transcription Factor | 1 | 2001 | 4 | 0.010 |
Why?
|
Cyclin D2 | 1 | 2001 | 6 | 0.010 |
Why?
|
Enhancer Elements, Genetic | 1 | 2001 | 18 | 0.010 |
Why?
|
Response Elements | 1 | 2001 | 14 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2001 | 47 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 2001 | 42 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2001 | 83 | 0.010 |
Why?
|
Binding Sites | 1 | 2001 | 116 | 0.010 |
Why?
|
Recurrence | 1 | 2001 | 236 | 0.010 |
Why?
|
Cell Line | 1 | 2001 | 417 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2001 | 477 | 0.010 |
Why?
|
Signal Transduction | 1 | 2001 | 688 | 0.010 |
Why?
|
Cognition Disorders | 1 | 1999 | 407 | 0.010 |
Why?
|